Clinical Trial Update: The Safety and Efficacy for In-segment Late Lumen Loss of the 'Genoss® SCB' Versus 'SeQuent® Please NEO' in Patients With Coronary ISR [NA]

View source ↗

Summary

Clinical trial update describing an enrolling-by-invitation study comparing Genoss SCB and SeQuent Please NEO drug-coated balloons for in-segment late lumen los…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Genoss SCB (sirolimus-coated balloon)
• SeQuent Please NEO (paclitaxel-coated balloon)

Snippet

Sponsor: Genoss Co., Ltd. | Conditions: Coronary Arterial Disease (CAD) | NA | Status: ENROLLING_BY_INVITATION